Conflict of interest statement: CONFLICTS OF INTEREST The authors declare thatthey have no competing interests.41. Oncotarget. 2018 Jun 26;9(49):29112-29122. doi: 10.18632/oncotarget.25631.eCollection 2018 Jun 26.Resveratrol prevents p53 aggregation in vitro and in breast cancer cells.Ferraz da Costa DC(1)(2), Campos NPC(2)(3), Santos RA(1), Guedes-da-SilvaFH(2)(3), Martins-Dinis MMDC(2)(3), Zanphorlin L(4), Ramos C(4), Rangel LP(2)(5),Silva JL(2)(3).Author information: (1)Departamento de Nutrição Básica e Experimental, Instituto de Nutrição,Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, RJ, Brazil.(2)Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem,Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.(3)Programa de Biologia Estrutural, Instituto de Bioquímica Médica Leopoldo deMeis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ,Brazil.(4)Instituto de Química, Universidade de Campinas, Campinas 13083-970, SP,Brazil.(5)Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia,Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.One potential target for cancer therapeutics is the tumor suppressor p53, whichis mutated in more than 50% of malignant tumors. Loss of function (LoF), dominantnegative (DN) and gain of function (GoF) mutations in p53 are associated withamyloid aggregation. We tested the potential of resveratrol, a naturallyoccurring polyphenol, to interact and prevent the aggregation of wild-type andmutant p53 in vitro using fluorescence spectroscopy techniques and in humanbreast cancer cells (MDA-MB-231, HCC-70 and MCF-7) using immunofluorescenceco-localization assays. Based on our data, an interaction occurs betweenresveratrol and the wild-type p53 core domain (p53C). In addition, resveratroland its derivatives pterostilbene and piceatannol inhibit mutant p53C aggregationin vitro. Additionally, resveratrol reduces mutant p53 protein aggregation inMDA-MB-231 and HCC-70 cells but not in the wild-type p53 cell line MCF-7. Toverify the effects of resveratrol on tumorigenicity, cell proliferation and cell migration assays were performed using MDA-MB-231 cells. Resveratrol significantlyreduced the proliferative and migratory capabilities of these cells. Our studyprovides evidence that resveratrol directly modulates p53, enhancing ourunderstanding of the mechanisms involved in p53 aggregation and its potential as a therapeutic strategy for cancer treatment.DOI: 10.18632/oncotarget.25631 PMCID: PMC6044377PMID: 30018739 